Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (401-410 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|October 1, 1987
Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritisD E Furst, E Sarkissian, K Blocka, et al.
Clinical Rheumatology|February 13, 2019
Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature reviewYukai Wang, Shaoqi Chen, Zhangzhang Lin, et al.
Rheumatology (Oxford, England)|July 17, 2009
Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trialsMarian Kaldas, Puja P Khanna, Daniel E Furst, et al.
Arthritis Care & Research|October 10, 2012
Publication outcomes of abstracts presented at an American College of Rheumatology/Association of Rheumatology Health Professionals annual scientific meetingGil Amarilyo, Jennifer M P Woo, Daniel E Furst, et al.
Rheumatology (Oxford, England)|October 2, 2010
Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosisVijay Bodukam, Ron D Hays, Paul Maranian, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release TofacitinibM Lamba, M M Hutmacher, D E Furst, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
The Journal of Rheumatology|July 5, 2011
Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract InstrumentDinesh Khanna, Daniel E Furst, Paul Maranian, et al.
The Journal of Rheumatology|May 22, 2001
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth, D E Furst, V Strand, et al.
The Journal of Rheumatology|August 3, 2011
OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in healthJohn R Kirwan, Annelies Boonen, Mark J Harrison, et al.
Pageof 76

Showing results (401-410 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|October 1, 1987
Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritisD E Furst, E Sarkissian, K Blocka, et al.
Clinical Rheumatology|February 13, 2019
Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature reviewYukai Wang, Shaoqi Chen, Zhangzhang Lin, et al.
Rheumatology (Oxford, England)|July 17, 2009
Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trialsMarian Kaldas, Puja P Khanna, Daniel E Furst, et al.
Arthritis Care & Research|October 10, 2012
Publication outcomes of abstracts presented at an American College of Rheumatology/Association of Rheumatology Health Professionals annual scientific meetingGil Amarilyo, Jennifer M P Woo, Daniel E Furst, et al.
Rheumatology (Oxford, England)|October 2, 2010
Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosisVijay Bodukam, Ron D Hays, Paul Maranian, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release TofacitinibM Lamba, M M Hutmacher, D E Furst, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
The Journal of Rheumatology|July 5, 2011
Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract InstrumentDinesh Khanna, Daniel E Furst, Paul Maranian, et al.
The Journal of Rheumatology|May 22, 2001
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth, D E Furst, V Strand, et al.
The Journal of Rheumatology|August 3, 2011
OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in healthJohn R Kirwan, Annelies Boonen, Mark J Harrison, et al.
Pageof 76